Business & Industry News Channel
Abbott announced that it has received CE Mark (Conformite Europeenne) for its next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. The company plans to launch XIENCE PRIME in a broad size matrix with lengths up to 38 mm in Europe in the third quarter.
Nycomed received marketing authorisation from the European Commission for five applications: PANTOZOL Control®, PANTOLOC Control®, PANTECTA Control®, SOMAC Control® and CONTROLOC Control®. This new OTC medication is intended for short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults as a medicinal product not subject to medical prescription.
GlaxoSmithKline plc (GSK) has announced an agreement with Dr. Reddy's Laboratories Ltd (Dr. Reddy's) to develop and market selected products across an extensive number of emerging markets, excluding India.
Boehringer Ingelheim and Vitae Pharmaceuticals, Inc., announced today that they have entered into a significant worldwide collaboration to research and develop beta-secretase (BACE) inhibitors for the treatment of Alzheimer's disease. Current therapies for Alzheimer's disease can improve symptoms, but do not affect the progression of the disease. 
Genzyme Corporation (Nasdaq: GENZ) announced that the European Commission has approved Renvela® (sevelamer carbonate) for the control of serum phosphorus in patients with chronic kidney disease (CKD). The approval includes patients not on dialysis with serum phosphorus levels ≥ 1.78 mmol/L (5.5 mg/dL), and covers both the tablet and powder formulations.
Results from the Rheumatoid Arthritis: Insights, Strategies & Expectations (RAISE) survey of more than 500 rheumatoid arthritis (RA) patients throughout Europe and Canada revealed a majority of patients still suffer from pain (79 percent), fatigue (67 percent) and joint stiffness (57 percent) on a regular basis despite current treatment, while more than half (51 percent) of RA patients feel their disease controls their life.
The Lancet has published online the results of the LEAD™ 6 study, a direct comparison between two products in a new class of diabetes treatments, the GLP-1 receptor agonists. Results show that patients treated with liraglutide had a statistically greater drop in HbA1c than those who received exenatide.